Treatment of multiple sclerosis

The first disease-modifying therapy for relapsing–remitting multiple sclerosis — interferon‑β 1b — was approved by the FDA in 1993. The following 25 years have seen rapid expansion of the therapeutic options as an evolving understanding of the disease has enabled development of therapies with different modes of action. As a result, we now have a complex treatment landscape that includes various injectables, oral drugs and monoclonal antibodies, each of which has its own advantages and risks. This Milestone tracks the development of the treatment of multiple sclerosis on an interactive Timeline, from the approval of the first disease-modifying therapy to the latest breakthroughs that have seen unprecedented efficacy and approval of the first drug for primary progressive multiple sclerosis.

This Milestone is editorially independent, produced with financial support from a third party. About this content.


NR Neurology Reviews

Additional Reviews and Research

News and comment